Severe liver dysfunction in a patient with multiple sclerosis: the guilty party is not always the disease-modifying therapy.
Hotermans
C
C
Belachew
S
S
Moonen
G
G
Delwaide
J
J
D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D056486:Chemical and Drug Induced Liver Injury / Q000150:complications* / Q000209:etiology; D005260:Female; D000068717:Glatiramer Acetate; D006801:Humans; D007052:Ibuprofen / Q000009:adverse effects*; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D007370:Interferon Type I / Q000009:adverse effects* / Q000627:therapeutic use; D008111:Liver Function Tests; D009103:Multiple Sclerosis / Q000150:complications*; D010455:Peptides / Q000009:adverse effects* / Q000627:therapeutic use; D011994:Recombinant Proteins
D000894:Anti-Inflammatory Agents, Non-Steroidal; D007166:Immunosuppressive Agents; D007370:Interferon Type I; D010455:Peptides; D011994:Recombinant Proteins; D000068717:Glatiramer Acetate; D007052:Ibuprofen